2. Immunology/Inflammation
  3. NO Synthase
  4. Hydroxocobalamin acetate

Hydroxocobalamin acetate  (Synonyms: Vitamin B12a acetate)

Cat. No.: HY-B2209B Purity: ≥98.0%
SDS
COA
Handling Instructions Technical Support

Hydroxocobalamin acetate is an injectable natural vitamin B12. Hydroxocobalamin acetate binds to NO. Hydroxocobalamin acetate detoxifies Cyanide and NaSH. Hydroxocobalamin acetate reduces hypotension. Hydroxocobalamin acetate is used in research related to vitamin B12 deficiency, including pernicious anemia.

For research use only. We do not sell to patients.

Hydroxocobalamin acetate Chemical Structure

Hydroxocobalamin acetate Chemical Structure

CAS No. : 22465-48-1

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
250 mg In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Hydroxocobalamin acetate:

Hydroxocobalamin acetate Related Antibodies

Top Publications Citing Use of Products

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Hydroxocobalamin acetate is an injectable natural vitamin B12. Hydroxocobalamin acetate binds to NO. Hydroxocobalamin acetate detoxifies Cyanide and NaSH. Hydroxocobalamin acetate reduces hypotension. Hydroxocobalamin acetate is used in research related to vitamin B12 deficiency, including pernicious anemia[1][2][3][4][5][6][7][8].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

Hydroxocobalamin (1 mM) acetate shows no significant improvement in key mitochondrial respiratory states and no attenuation of superoxide production in Cyanide-poisoned peripheral blood mononuclear cells (PBMC) and human aortic smooth muscle cells (HASMC)[4].
Hydroxocobalamin (50-100 μM) acetate prevents hepatocyte cytotoxicity induced by NaSH in isolated rat hepatocytes[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Hydroxocobalamin acetate Related Antibodies
In Vivo

Hydroxocobalamin (20 mg/kg; i.v.; single dose) acetate attenuates hypotension and increases in plasma reactive nitrogen intermediates (RNI), enhances urinary excretion of RNI, and decreases mortality in LPS (HY-D1056A3)-treated mice and rats[5].
Hydroxocobalamin (25-50 mg/kg; i.v.; 14 days) acetate significantly reduces Cyanide toxicity in rats ingesting Amygdalin (HY-N0190)[6].
Hydroxocobalamin (75-150 mg/kg; i.v.) acetate significantly reduces mortality from Potassium cyanide poisoning in adult beagle dogs, and is associated with cardiovascular recovery and improvement in acid-base status[7].
Hydroxocobalamin (0.25 mmol/kg; i.p.; 2 min after NaSH administration) acetate effectively prevents NaSH-induced death in mice at 24 h[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar strain albino rats (weight 150-165 g) with Cyanide poisoning induced by oral Amygdalin ingestion[6]
Dosage: 25 mg/kg or 50 mg/kg
Administration: Intravenous injection, 14 days
Result: Reduced blood cyanide and serum lactate levels in a dose-dependent manner.
Normalized packed cell volume (PCV), haemoglobin concentration, and blood pH.
Prevented histological alterations in the liver, with no significant histological change in the colour and size of the hepatic lobes.
Animal Model: Adult beagle dogs (male and female, mean weight 8.9-9.2 kg) with acute cyanide poisoning induced by intravenous Potassium cyanide infusion[7]
Dosage: 75 mg/kg or 150 mg/kg
Administration: Intravenous infusion
Result: Significantly reduced mortality rate.
Caused 15 of 19 animals to survive through 14 days at 75 mg/kg, and all 18 animals survived through 14 days at 150 mg/kg.
Led to rapid cardiovascular recovery, with increased blood pressure starting 1-3 min after infusion.
Improved acid-base status, with lower arterial lactate concentrations and higher arterial pH values.
Clinical Trial
Molecular Weight

1405.40

Formula

C64H92CoN13O17P-
CAS No.
Appearance

Solid

Color

Brown to black

SMILES

C[C@@]12[N]([Co+3]34([N]5=C[N@@]([C@@H](O[C@H](CO)[C@H]6OP7([O-])=O)[C@@H]6O)C8=C5C=C(C)C(C)=C8)([OH-])([O-]C(C)=O)[N-]9C2[C@H](CC(N)=O)[C@@](C)(CCC(NC[C@H](C)O7)=O)C9=C(C)C([C@@H](CCC(N)=O)C%10(C)C)=[N]3C%10=CC%11=[N]4C([C@](CC(N)=O)(C)[C@@H]%11CCC(N)=O)=C%12C)=C%12[C@@H](CCC(N)=O)[C@]1(C)CC(N)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (71.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.7115 mL 3.5577 mL 7.1154 mL
5 mM 0.1423 mL 0.7115 mL 1.4231 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (1.78 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (1.78 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.7115 mL 3.5577 mL 7.1154 mL 17.7885 mL
5 mM 0.1423 mL 0.7115 mL 1.4231 mL 3.5577 mL
10 mM 0.0712 mL 0.3558 mL 0.7115 mL 1.7789 mL
15 mM 0.0474 mL 0.2372 mL 0.4744 mL 1.1859 mL
20 mM 0.0356 mL 0.1779 mL 0.3558 mL 0.8894 mL
25 mM 0.0285 mL 0.1423 mL 0.2846 mL 0.7115 mL
30 mM 0.0237 mL 0.1186 mL 0.2372 mL 0.5930 mL
40 mM 0.0178 mL 0.0889 mL 0.1779 mL 0.4447 mL
50 mM 0.0142 mL 0.0712 mL 0.1423 mL 0.3558 mL
60 mM 0.0119 mL 0.0593 mL 0.1186 mL 0.2965 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Hydroxocobalamin acetate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Hydroxocobalamin22465-48-1Vitamin B12aNO SynthaseNitric oxide synthasesNOSalbino rats beagle dogsmiceHASMCPBMChypotensionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Hydroxocobalamin acetate
Cat. No.:
HY-B2209B
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (419 KB) Français - FR (419 KB) Deutsch - DE (419 KB) Norwegian - NO (419 KB) Español - ES (419 KB) Swedish - SV (419 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.